<head>
    <!-- Stylesheet -->
    <link rel="stylesheet" href="css/safety.css">
</head>
<!-- Main -->
<main>
    <div class="tabs">
        <a href="safety.html" class="tab tab--active">SAFETY</a>
        <a href="tolerability.html" class="tab">TOLERABILITY</a>
    </div>
    <h2 class="primary">Duration of Exposure and Incidence of Adverse Events (AEs)</h2>
    
    <h3 class="secondary-variant">AEs occurring in ≥10% of patients (N = 129) with R/R PTCL (NCI-CTCAE grades 1 to 4)<sup>1</sup></h3>

    <div class="patient-aes">
        <img src="assets/svg/safety/safety-chart.svg" alt="AEs occurring in ≥10% of patients (N = 129) with R/R PTCL (NCI-CTCAE grades 1 to 4)"/>
        <ul>
            <h4 class="semibold">Duration of Exposure</h4>
            <li>
                <h4 class="light">Most patients (113 of 129) remained on the target dose (1000 mg/m2)<sup>1,2</sup>
                <ul>
                    <li>Dosage adjustments due to AEs occurred in 16 of 129 patient treated with BELEODAQ</li>
                </ul>
                </h4>
            </li>
            <li>
                <h4 class="light">The relative dose intensity (doses administered vs planned) was 98%<sup>2</sup></h4>
            </li>
            <li>
                <h4 class="light">Treatment duration ranged from 1 to 33 cycles (median, 2 cycles)<sup>1,2</sup></h4>
            </li>
            <h4 class="semibold">Adverse Events</h4>
            <li>
                <h4 class="light">Twenty-five patients (19.4%) discontinued treatment with BELEODAQ due to AEs<sup>1</sup>
                    <ul>
                        <li>The AEs reported most frequently as the reason for discontinuation of treatment included anemia, febrile neutropenia, fatigue, and multi-organ failure</li>
                    </ul>
                </h4>
            </li>
            <li>
                <h4 class="light">Treatment-emergent AEs (TEAEs) occurred in 97% of patients and were generally mild to moderate in severity<sup>2</sup>
                <ul>
                    <li>The most common AEs were nausea, fatigue, pyrexia, anemia, and vomiting</li>
                </ul></h4>
            </li>
            <li>
                <h4 class="light">Grade 3/4 AEs occurring in ≥5% of patients (N = 129) were anemia (11%), thrombocytopenia (7%), dyspnea (6%), and fatigue (5%)<sup>1</sup></h4>
            </li>
            <li>
                <h4 class="light">47% (n = 61) experienced serious AEs (SAEs)<sup>1,2</sup>
                <ul>
                    <li>
                        No clinically meaningful difference in SAEs was observed in patients based on age (&lt;65 years vs &lt;65 years or &lt;75 years vs ≥75 years)
                    </li>
                </ul></h4>
            </li>
        </ul>
    </div>
    <p class="light">NCI-CTCAE, National Cancer Institute Common Terminology Criteria for 
        Adverse Events. <br>
        <span class="semibold">Note</span>: AEs are listed by order of incidence in the all-grades category ﬁrst, 
        then in the grades 3 to 4 category; measured by NCI-CTCAE version 3.0.</p>
    <p class="light">AEs, adverse events; PTCL, peripheral T-cell lymphoma; LDH, lactate dehydrogenase; R/R, relapsed/refractory; SAEs, serious AEs; TEAEs, treatment-emergent AEs. 
    </p>
    <div class="button-group">
        <a href="efficacy.html" class="button secondary"><i class="fas fa-chevron-left"></i> Efficacy</a>
        <a href="dosing.html" class="button">Dosing & Administration <i class="fas fa-chevron-right"></i></a>
    </div>
</main>